Clinical use of mood stabilizers with antidepressants in Asia: Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013

Kamini Rajaratnam, Yu Tao Xiang, Adarsh Tripathi, Helen F.K. Chiu, Tian Mei Si, Kok Yoon Chee, Ajit Avasthi, Sandeep Grover, Mian Yoon Chong, Hironori Kuga, Shigenobu Kanba, Yan Ling He, Min-Soo Lee, Shu Yu Yang, Pichet Udomratn, Roy A. Kallivayalil, Andi J. Tanra, Margarita M. Maramis, Winston W. Shen, Norman SartoriusEe Heok Kua, Chay Hoon Tan, Rathi Mahendran, Naotaka Shinfuku, Min Yi Sum, Ross J. Baldessarini, Kang Sim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.

Original languageEnglish
Pages (from-to)255-259
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume37
Issue number2
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Antidepressive Agents
Prescriptions
Psychiatry
Research
Bipolar Disorder
Mentally Ill Persons
Ambulatory Care
Anxiety Disorders
Inpatients
Hospitalization
Therapeutics
Cross-Sectional Studies
Logistic Models
Depression

Keywords

  • antidepressant
  • anxiety
  • bipolar disorder
  • major depression
  • mood stabilizer

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Clinical use of mood stabilizers with antidepressants in Asia : Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013. / Rajaratnam, Kamini; Xiang, Yu Tao; Tripathi, Adarsh; Chiu, Helen F.K.; Si, Tian Mei; Chee, Kok Yoon; Avasthi, Ajit; Grover, Sandeep; Chong, Mian Yoon; Kuga, Hironori; Kanba, Shigenobu; He, Yan Ling; Lee, Min-Soo; Yang, Shu Yu; Udomratn, Pichet; Kallivayalil, Roy A.; Tanra, Andi J.; Maramis, Margarita M.; Shen, Winston W.; Sartorius, Norman; Kua, Ee Heok; Tan, Chay Hoon; Mahendran, Rathi; Shinfuku, Naotaka; Sum, Min Yi; Baldessarini, Ross J.; Sim, Kang.

In: Journal of Clinical Psychopharmacology, Vol. 37, No. 2, 01.04.2017, p. 255-259.

Research output: Contribution to journalArticle

Rajaratnam, K, Xiang, YT, Tripathi, A, Chiu, HFK, Si, TM, Chee, KY, Avasthi, A, Grover, S, Chong, MY, Kuga, H, Kanba, S, He, YL, Lee, M-S, Yang, SY, Udomratn, P, Kallivayalil, RA, Tanra, AJ, Maramis, MM, Shen, WW, Sartorius, N, Kua, EH, Tan, CH, Mahendran, R, Shinfuku, N, Sum, MY, Baldessarini, RJ & Sim, K 2017, 'Clinical use of mood stabilizers with antidepressants in Asia: Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013', Journal of Clinical Psychopharmacology, vol. 37, no. 2, pp. 255-259. https://doi.org/10.1097/JCP.0000000000000670
Rajaratnam, Kamini ; Xiang, Yu Tao ; Tripathi, Adarsh ; Chiu, Helen F.K. ; Si, Tian Mei ; Chee, Kok Yoon ; Avasthi, Ajit ; Grover, Sandeep ; Chong, Mian Yoon ; Kuga, Hironori ; Kanba, Shigenobu ; He, Yan Ling ; Lee, Min-Soo ; Yang, Shu Yu ; Udomratn, Pichet ; Kallivayalil, Roy A. ; Tanra, Andi J. ; Maramis, Margarita M. ; Shen, Winston W. ; Sartorius, Norman ; Kua, Ee Heok ; Tan, Chay Hoon ; Mahendran, Rathi ; Shinfuku, Naotaka ; Sum, Min Yi ; Baldessarini, Ross J. ; Sim, Kang. / Clinical use of mood stabilizers with antidepressants in Asia : Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013. In: Journal of Clinical Psychopharmacology. 2017 ; Vol. 37, No. 2. pp. 255-259.
@article{8d2ed438331e43a183a45297caccc7ea,
title = "Clinical use of mood stabilizers with antidepressants in Asia: Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013",
abstract = "Objective As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results Use of MS + AD increased by 104{\%} (5.5{\%} to 11.2{\%}) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.",
keywords = "antidepressant, anxiety, bipolar disorder, major depression, mood stabilizer",
author = "Kamini Rajaratnam and Xiang, {Yu Tao} and Adarsh Tripathi and Chiu, {Helen F.K.} and Si, {Tian Mei} and Chee, {Kok Yoon} and Ajit Avasthi and Sandeep Grover and Chong, {Mian Yoon} and Hironori Kuga and Shigenobu Kanba and He, {Yan Ling} and Min-Soo Lee and Yang, {Shu Yu} and Pichet Udomratn and Kallivayalil, {Roy A.} and Tanra, {Andi J.} and Maramis, {Margarita M.} and Shen, {Winston W.} and Norman Sartorius and Kua, {Ee Heok} and Tan, {Chay Hoon} and Rathi Mahendran and Naotaka Shinfuku and Sum, {Min Yi} and Baldessarini, {Ross J.} and Kang Sim",
year = "2017",
month = "4",
day = "1",
doi = "10.1097/JCP.0000000000000670",
language = "English",
volume = "37",
pages = "255--259",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical use of mood stabilizers with antidepressants in Asia

T2 - Report from the research on asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013

AU - Rajaratnam, Kamini

AU - Xiang, Yu Tao

AU - Tripathi, Adarsh

AU - Chiu, Helen F.K.

AU - Si, Tian Mei

AU - Chee, Kok Yoon

AU - Avasthi, Ajit

AU - Grover, Sandeep

AU - Chong, Mian Yoon

AU - Kuga, Hironori

AU - Kanba, Shigenobu

AU - He, Yan Ling

AU - Lee, Min-Soo

AU - Yang, Shu Yu

AU - Udomratn, Pichet

AU - Kallivayalil, Roy A.

AU - Tanra, Andi J.

AU - Maramis, Margarita M.

AU - Shen, Winston W.

AU - Sartorius, Norman

AU - Kua, Ee Heok

AU - Tan, Chay Hoon

AU - Mahendran, Rathi

AU - Shinfuku, Naotaka

AU - Sum, Min Yi

AU - Baldessarini, Ross J.

AU - Sim, Kang

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.

AB - Objective As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.

KW - antidepressant

KW - anxiety

KW - bipolar disorder

KW - major depression

KW - mood stabilizer

UR - http://www.scopus.com/inward/record.url?scp=85011317364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011317364&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000670

DO - 10.1097/JCP.0000000000000670

M3 - Article

C2 - 28146001

AN - SCOPUS:85011317364

VL - 37

SP - 255

EP - 259

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -